Seres Therapeutics is a microbiome therapeutics platform company developing a class of live biotherapeutic drugs. SER-109, Co.'s lead clinical candidate is an oral, purified bacterial spore-based microbiome therapeutic candidate consisting of a consortium of purified bacteria. Using Co.'s microbiome therapeutics platform, Co. is focusing its resources on obtaining clinical results from its clinical programs in ulcerative colitis, a form of inflammatory bowel disease with SER-287 and SER-301, with SER-401 in patients with metastatic melanoma, and with SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease in immunocompromised patients. The MCRB stock yearly return is shown above.
The yearly return on the MCRB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MCRB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|